You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

niraparib

Showing 1 - 25 of 113
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Trial in Beijing (Niraparib)

Recruiting
  • Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
  • Niraparib
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Nov 15, 2023

Safety of Niraparib in Korean Primary and Recurrent Epithelial

Completed
  • Epithelial Ovarian Cancer
  • Niraparib
  • Seoul, Korea, Republic of
    Department of Obstetrics and Gynecology, University of Ulsan Col
Oct 11, 2023

Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer Trial in Toronto (Niraparib)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • Niraparib
  • Toronto, Ontario, Canada
    Sunnybrook Research Institute
Jul 18, 2023

Recurrent Glioblastoma Trial (Niraparib, Re-irradiation (re-RT))

Not yet recruiting
  • Recurrent Glioblastoma
  • Niraparib
  • Re-irradiation (re-RT)
  • (no location specified)
Dec 23, 2022

Ovarian Tumors Trial in Nanjing (Niraparib)

Completed
  • Ovarian Neoplasms
  • Niraparib
  • Nanjing, China
    Zhongda hospital
Feb 17, 2023

Tumors Trial in United States (GSK4524101, Niraparib)

Not yet recruiting
  • Neoplasms
  • San Francisco, California
  • +5 more
Oct 5, 2023

Head and Neck Squamous Cell Carcinoma Trial in Spain (Dostarlimab, Niraparib, cisplatin plus radiotherapy)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Badalona, Cataluña, Spain
  • +4 more
Mar 13, 2023

Head Neck Cancer Trial in Cincinnati, Columbus (Niraparib, Dostarlimab)

Active, not recruiting
  • Head and Neck Cancer
  • Cincinnati, Ohio
    University of Cincinnati Medical Center
Jan 31, 2023

Brain Metastases Trial in Houston (Niraparib, Dostarlimab)

Not yet recruiting
  • Brain Metastases
  • Houston, Texas
    M D Anderson Cancer Center
Jan 17, 2023

Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma Trial in Boston (Niraparib, Resection/Treatment with Niraparib)

Recruiting
  • Low-grade Glioma
  • +4 more
  • Niraparib
  • Resection/Treatment with Niraparib
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 19, 2022

Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma Trial in Gainesville, Miami, Orlando (Niraparib)

Completed
  • Mesothelioma
  • +3 more
  • Niraparib
  • Gainesville, Florida
  • +2 more
Jan 4, 2023

Recurrent Endometrial Serous Adenocarcinoma Trial in Columbus (procedure, biological, drug)

Not yet recruiting
  • Recurrent Endometrial Serous Adenocarcinoma
  • Biospecimen Collection
  • +4 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 12, 2023

Niraparib in Patients With Ovarian Cancer in Clinical Practice

Recruiting
  • Ovarian Cancer
  • Niraparib
  • Tokyo, Japan
    Takeda Selected Site
Oct 21, 2022

Ovarian Cancer Trial in Chengdu (Yangzheng Xiaoji, Niraparib)

Not yet recruiting
  • Ovarian Cancer
  • Yangzheng Xiaoji
  • Niraparib
  • Chengdu, Sichuan, China
    Sicchuan cancer hospital
Nov 30, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Biopsy
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Sacramento (Niraparib, Niraparib Tosylate Monohydrate,

Recruiting
  • ATM Gene Mutation
  • +16 more
  • Niraparib
  • +2 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 27, 2022

Esophageal Cancer, Gastric Cancer, Adenocarcinoma Trial in United States (Niraparib)

Recruiting
  • Esophageal Cancer
  • +2 more
  • Niraparib
  • Tampa, Florida
  • +3 more
Jan 18, 2023

Ovarian Tumor Trial in United States (Dostarlimab, Bevacizumab, Niraparib)

Completed
  • Ovarian Neoplasm
  • Birmingham, Alabama
  • +9 more
Feb 20, 2023

Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)

Not yet recruiting
  • Metastatic Solid Tumor
  • +4 more
  • San Francisco, California
    University of California, San Francisco
Jan 12, 2023

HRD, Cholangiocarcinoma, Metastatic Cancer Trial (Niraparib, Dostarlimab)

Withdrawn
  • HRD
  • +2 more
  • (no location specified)
Jun 23, 2022

Metastatic Breast Cancer, HER2 Positive Breast Carcinoma Trial in United States (Niraparib, Trastuzumab)

Recruiting
  • Metastatic Breast Cancer
  • HER2 Positive Breast Carcinoma
  • Birmingham, Alabama
  • +6 more
Dec 13, 2022

Metastatic Pancreatic Cancer Trial in Lyon (Niraparib)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Niraparib
  • Lyon, France
    Centre Léon Bérard
Jul 4, 2022

Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer Trial (Niraparib, Dostarlimab)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 26, 2022

Rectal Tumors, Rectal Tumor Malignant Trial in Iowa City (Niraparib, Dostarlimab, Short course radiation)

Recruiting
  • Rectal Neoplasms
  • Rectal Neoplasm Malignant
  • Niraparib
  • +2 more
  • Iowa City, Iowa
    Holden Comprehensive Cancer Center at the University of Iowa
Jul 22, 2022

Tumors Trial in France, Spain, United Kingdom (Niraparib, Dostarlimab)

Recruiting
  • Neoplasms
  • Brno, Czechia
  • +20 more
Nov 21, 2022